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Background:  Despite  an  increased  number  of economic  evaluations  of tobacco  control  inter-
ventions, the  uptake  by  stakeholders  continues  to be limited.  Understanding  the  underlying
mechanism  in adopting  such  economic  decision-support  tools  by stakeholders  is  therefore
important.  By applying  the  I-Change  Model,  this  study  aims  to identify  which  factors  deter-
mine potential  uptake  of an  economic  decision-support  tool,  i.e.,  the  Return  on  Investment
tool.
Methods:  Stakeholders  (decision-makers,  purchasers  of services/pharma  products,  profes-
sionals/service  providers,  evidence  generators  and advocates  of  health  promotion)  were
interviewed  in  ﬁve  countries,  using  an I-Change  based  questionnaire.  MANOVA’s  were
conducted  to assess  differences  between  intenders  and non-intenders  regarding  beliefs.
A multiple  regression  analysis  was  conducted  to identify  the main  explanatory  variables  of
intention  to  use  an economic  decision-support  tool.
Findings:  Ninety-three  stakeholders  participated.  Signiﬁcant  differences  in beliefs  were
found between  non-intenders  and  intenders:  risk perception,  attitude,  social  support,
and  self-efﬁcacy  towards  using  the tool.  Regression  showed  that  demographics,  pre-
motivational,  and  motivational  factors  explained  69% of the variation  in  intention.
Discussion: This  study  is 
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. Introduction
Tobacco smoking is a worldwide health and economic
roblem. In Europe estimated costs of smoking tobacco are
ust above 1% of the EU Gross Domestic Product in 2000
1]. Tobacco continues to adversely inﬂuence global health,
ccounting for 6.9% of life years lost, and 5.5% of disability-
djusted life-years in 2010 [2,3]. The WHO  Framework
onvention on Tobacco Control [4] has been ratiﬁed by EU
ember states [5], suggesting that more effort needs to be
irected towards tackling tobacco smoking in the European
ommunity at all levels, including public health research
6]. Due to limited resources available for tobacco control,
ealth-care budget holders may  have a need to set pri-
rities regarding choices for smoking cessation methods,
aking it relevant to know whether the societal beneﬁts
f these methods are worth the investments that have to
e made [7]. The information of cost-effectiveness studies
ay  provide value to the policy process. As many health
onsequences of tobacco smoking manifest in the long-
erm, model-based economic evaluations may  provide
articular valuable information for stakeholders of tobacco
ontrol. To give an overview in costs and beneﬁts, several
model-based) economic evaluations of tobacco control
ethods have already been conducted, including pharma-
ological and psychological interventions [8–15].
Using an earlier model-based economic evaluation tool
16], Brunel University London, the National Institute of
ealth and Clinical Excellence [NICE], and regional tobacco
ontrol organisations in England developed and tested the
obacco Return on Investment Tool (hereafter ‘ROI tool’)
n 2012. This tool aims to help decision-makers under-
tand the return on investment of their chosen package
f tobacco control interventions, which may  include a mix
f pharmacological and behavioural support components.
he tool includes an interface to select the geograph-
cal area of interest, resulting in estimates of smoking
revalence in particular countries and regions within a
ountry. Additionally, the impact of smoking on relevant
utcomes is modelled taking into account several time
orizons. EQUIPT (European-study on the Quantifying Util-
ty of Investment in Protection from Tobacco) has the
mbition of developing and disseminating a new version
f the ROI tool across Europe [17].
Disseminating economic decision-support tools, such
s the ROI tool, may  be a challenge. Despite the fact that
he amount of cost-effectiveness information has increased
ver the last decades, the uptake by stakeholders of these
conomic evaluations to aid their decision-making contin-
es to be limited [11,18,19]. For instance, limited uptake of
conomic evaluation information was reported in research
nto policy decision-making in the UK [20], and in a number
f European health care systems [21,22]. The availability
f cost-effectiveness information does not automatically
ranslate into the adoption of the most cost-effective inter-
ention. For instance, in the Netherlands internet-based
omputer tailoring for smoking cessation has been shown
o be highly cost-effective [14], and yet these interventions
ave currently not been adopted by national agencies.
Explanations for the limited impact on health policy
f economic evidence have been explored [23]. Multiplecy 120 (2016) 46–54 47
barriers to the use of cost-effectiveness information have
been identiﬁed [11,18,24], including uncertainty in the
quality of the studies [19], limited applicability of the eco-
nomic evaluation studies for the setting of the stakeholders
[18], limited economic evaluation knowledge of several
stakeholders [18,19], negative attitude towards scientiﬁc
evidence, lack of tools and skills to interpret scientiﬁc
evidence, no perception of relevance of research, lack of
support for management and front-line staff, and difﬁculty
of applying evidence in the local context [11]. Moreover,
it is important to consider timeliness and relevance of
research as well as stakeholders’ trust in the source of evi-
dence [11].
Whilst the above studies identify key barriers for stake-
holders to use available economic evidence, literature does
not provide a framework of the underlying mechanism
by which potential facilitators and barriers to the uptake
of evidence in decision-making processes come into play.
Previous studies identiﬁed important factors related to
the uptake (or non-uptake) of cost effectiveness informa-
tion in health policy decisions [23,25]. However, these
theories focused less on the motives of stakeholders for
uptake or non-uptake, which is the focus of the current
study that uses an integration of social cognitive models to
understand these motives. This approach also allows us to
identify potential strategies to increase levels of motivation
of the stakeholders.
The goal of the study is therefore twofold: (1) to explore
beliefs about an economic decision-support tool of tobacco
control that determine stakeholders’ intention to use such
a tool; and (2) to investigate which theoretical concepts
determine stakeholders’ intention to adopt such tool.
2. Method
2.1. Theoretical framework
We  applied the I-Change Model (see Fig. 1) [14,26–28]
to explain behaviour related to the uptake of any innova-
tion like a health economic decision model, by integrating
concepts of various health behaviours, – communica-
tion, and promotion models [29–33]. The I-Change model
has been used widely in identifying the determinants of
health behaviour and behaviour related to the uptake
of health promoting interventions [34–38]. The model
explains uptake of health behaviour and health behaviour
promoting policies in (at least) three phases (i.e., aware-
ness, motivation, and action phase), with each phase having
phase speciﬁc determinants. The model postulates that
the speciﬁc determinants are: knowledge, awareness, and
risk perceptions for understanding awareness (i.e., knowl-
edge and awareness of such evidence-based tools, and
perceived risks of not using such tools), and attitude (per-
ception of advantages and disadvantages towards such a
tool), social support (perception whether other people sup-
port the use of such a tool), and self-efﬁcacy (the perceived
ability to use such tool) for understanding motivation.
This leads to the intention to adopt certain behaviour
(i.e., uptake of such a tool). As the decision-support tool
in this study was  not yet available at the time of the
study, the action phase (i.e., developing and enactment
48 K.L. Cheung et al. / Health Policy 120 (2016) 46–54
Premovaon factors
(i.e. knowledge, risk-
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Movaon factors 
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Intenon Behaviour
Informaon factors
(i.e. personal, message, channel, source)
Predisposing factors
(i.e. behavioral, psychological, biological)
ge modeFig. 1. I-Chan
of action plans and skills to use such a tool) was not
relevant in this study. Intention is considered the most
proximal antecedent of behaviour in numerous theories in
social and health psychology. Meta-analysis of experimen-
tal studies of intention–behaviour relations showed that a
medium-to-large change in intention (d = 0.66) leads to a
small-to-medium change in behaviour (d = 0.36) [39]. Col-
lection of relevant data on each construct allowed us to
corroborate this model in its speciﬁc application to explain
stakeholders’ intention related to the uptake of an eco-
nomic decision-support tool.
2.2. Deﬁning the ‘innovation’
In order to examine important beliefs, and theoreti-
cal concepts that determine the stakeholder’s intention to
adopt an economic decision-support tool, we used the ROI
tool as an innovation. The ROI tool is a state-transition
cohort model with a cycle length of one year and assumes
the Markov property. The UK version of this economic
model is accessible online [9]. At this moment, the EQUIPT
study is developing a new version of the ROI tool to support
decision-making and information gathering for the stake-
holders of tobacco control. After selecting the country (or
a more speciﬁc area) of interest, the ROI tool populates
the model with country-speciﬁc estimates. The stakeholder
may  then view and amend the tobacco control measures
used in the current package. The tool then allows users to
explore the short, medium and long-term impact of dif-
ferent combinations of interventions and strategies (i.e., to
explore the impact of different scenarios). A video explain-
ing the upcoming ROI tool was created for this study to
explore beliefs (i.e., expectations) (see Supplementary ﬁle
1). The video outlines the functionality of the ROI tool with
England as example. It illustrates three aspects of the tool:
(1) how the ROI tool can highlight the impact of tobacco
on the local area, and that the ROI tool can (2) estimate
the impact of the current investment in tobacco control,
and (3) amend the existing provision of interventions. We
used this ROI tool as the ‘innovation’ to study stakeholders’
intention to use it in decision-making.l [14,26–28].
2.3. Data collection
A cross sectional survey with stakeholders (deﬁned
below) was  conducted in ﬁve European countries that are
covered by the EQUIPT Project (i.e., Germany, Hungary,
the Netherlands, Spain and the UK) [17]. Individual inter-
views – with average duration of approximately 30 min
– were conducted between April and July 2014, using
a speciﬁcally- designed questionnaire consisting of both
open-ended and multiple-choice questions. After assessing
beliefs regarding pre-motivational constructs (i.e., knowl-
edge, risk perception, and awareness), the participants
viewed the video explaining the upcoming ROI tool. The
purpose was  to enhance awareness and inform stakehol-
ders about the functions of the ROI tool. The interview
continued with the motivational constructs (i.e., attitude,
social support, and self-efﬁcacy) and the intention to take
up the ROI tool. A checklist was used for preparation and
reporting of this study (available from the ﬁrst author on
request), in accordance with the STROBE statement [40].
2.4. Participants
Stakeholders were identiﬁed through regular meetings
with participating EQUIPT partners. There was consen-
sus about ﬁve relevant categories of stakeholders of
tobacco control for economic decision-support tools:
decision-makers, purchasers of services/pharma prod-
ucts, professional service providers, evidence generators,
and advocates of health promotion. This description is
similar to the stakeholder deﬁnition by the Centre for
Disease Control and Prevention [41]. Decision-makers
with various different roles were included, for exam-
ple directors of public health services. Representatives
of purchasers of services/pharma products were high-
level decision-makers at insurance funds. Professional
service providers included leading physicians in smok-
ing cessation, physicians/psychologists, and coordinators
of local health programs. Evidence generators included
HTA professionals involved in the reimbursement proce-
dure, heads of local tobacco control organisations, experts
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n public health and health care costing, and researchers
n the area of smoking. Advocates of health promotion
ncluded were leaders of NGO’S or patient organisations,
or example the leader of a patient organisation for cancer
atients. Participants were recruited with a convenience
ampling strategy. The country teams (Germany, Hungary,
etherlands, Spain, and the UK) created a list of stakehol-
ers in each category based on their previous knowledge.
he stakeholders in that list were then approached with
 request to participate in this survey. They were also
sked to suggest additional names. The ﬁnal sample was
etermined by who responded positively at the end and,
herefore, it was not possible to predict a priori the compo-
ition of the ﬁnal sample.
.5. Questionnaire
A questionnaire was  designed speciﬁcally for this
urvey. The intention was to capture the beliefs of stakehol-
ers, regarding the constructs of the I-Change model. We
ssessed key background variables (i.e., country, gender,
nd the current professional role) of the respondent (which
ere ﬁlled in by the interviewers in advance) and stakehol-
ers’ beliefs about the ROI tool (which was collected during
he interview).
Following the concepts of the I-Change Model [26–28],
he questionnaire contained 12 questions (with multi-
le items) intending to measure stakeholders’ knowledge,
isk perception, awareness, attitude, social inﬂuences, self-
fﬁcacy, and intention to adopt the ROI tool. We  did not
ollect data to measure the action phase because the ROI
ool is not yet available to countries. Furthermore, several
uestions were asked in order to gain insight on how to best
iffuse the ROI tool (see Supplementary ﬁle 2 for the phras-
ng of each item). Several open-ended questions explored
ore information on each construct. All constructs were
easured using several items on a 7-point Likert scale
1 = strongly disagree, 7 = strongly agree with a statement).
verall scales were created by calculating the mean of the
tems for each construct, except for knowledge and aware-
ess (see below).
Awareness factors were assessed through items
ssessing knowledge and risk perception as well as one
verall item of awareness. Knowledge beliefs about HTA
ere assessed by asking stakeholders to what extent they
greed to ﬁve statements regarding economic evaluations.
o Cronbach’s  ˛ was calculated, as knowledge consists of
ultiple dimensions, resulting in an index variable. Risk
erception was assessed by asking stakeholders to rate to
hat extent they agreed with seven risk perception items.
or the regression analysis, three items were used that
reated an overall risk perception scale (  ˛ = 0.69). Over-
ll awareness of economic models was measured with one
tem asking whether stakeholders were aware of economic
odels or ﬁnancial tools regarding tobacco control (yes,
o).
Motivational factors were assessed through measure-
ents of attitude, social support, and self-efﬁcacy. Attitude
owards adopting the ROI tool was measured by assessing
he expected advantages and disadvantages of the ROI tool,
ith 12 items for advantages and 9 items for disadvantagescy 120 (2016) 46–54 49
[28]. For the regression analysis, items for disadvantages
were recoded to create an overall attitude scale (  ˛ = 0.91).
Social support for using the ROI tool was measured using
seven items assessing whom from the stakeholders’ col-
leagues/organisations would support them in adopting the
tool (  ˛ = 0.83). Self-efﬁcacy beliefs were assessed using 11
items to assess participants’ beliefs regarding the difﬁculty
they may  experience when adopting the ROI tool (  ˛ = 0.76).
Intention to use the ROI tool was  measured with four
items. The items assessed the extent to which stakeholders
agreed with statements that express the intention to adopt
the ROI tool (  ˛ = 0.91).
2.6. Piloting
The English version of the questionnaire was admin-
istered to a few colleagues in each country (n = 2–6) who
were not part of the study in a face-to-face meeting to
test its validity and practicality. The received feedback was
discussed widely in team meetings and a decision was
taken to revise the questionnaire to address the emerged
issues (e.g., questionnaire being too long, some questions
being irrelevant, and the need for a response scale to reﬂect
measurements of the level of agreement with a statement
rather than level of importance of an item). The revised
version was tested again by country-speciﬁc interview-
ers using the pilot sample. Following a few amendments
(mostly related to wording), the English version was trans-
lated to country-speciﬁc languages by native speakers.
Translated versions were pilot-tested again in each country
with at least one pilot respondent.
2.7. Interviews
Stakeholders were approached by an introductory reg-
ular mail or e-mail, sent by country-speciﬁc researchers.
The ﬁrst communication provided information about the
EQUIPT project and explained that any involvement in
the survey would be conﬁdential. An information sheet
and sample informed consent were also sent at the
same time. Once stakeholders agreed to participate, the
country-speciﬁc interviewer arranged both the date for
the interview and the mode of interview (face-to-face,
telephone, or skype). During the interview, stakeholders
received the questionnaire and were shown the video
explaining the ROI tool. Interviews were audio recorded.
In addition, the interviewers provided a much abbreviated
form of the qualitative response in the speciﬁed place in the
questionnaire. Microsoft Excel® was used for data-entry
and a double data entry procedure was conducted to min-
imise entry errors.
2.8. Analysis
The Excel data was exported to SPSS Statistics 22
format and the analysis was  conducted using SPSS soft-
ware. To explore beliefs that determine stakeholders’
intention to use the ROI tool, differences were identiﬁed
between stakeholders who do and do not intent to use
the ROI tool. Enhancing interpretability, the intention
scale was dichotomised into two  groups of stakeholders,
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Table  1
Differences between non-intenders and intenders in beliefs: risk perception; 1 = strongly disagree, 7 = strongly agree.
Non-intenders Intenders p-value Partial 2
Mean (SD) Mean (SD)
Risk perception
Smoking epidemic not severe in country (10A) 2.42 (1.59) 1.68 (1.08) 0.02* 0.07
Effectiveness of interventions (10B) 3.25 (1.62) 3.77 (1.58) 0.18 0.02
Cost-effective of interventions (10C) 3.63 (1.91) 4.15 (1.94) 0.27 0.02
Mortality of smoking (10D) 6.04 (1.30) 6.69 (0.67) <0.01* 0.10
Societal burden of smoking (10E) 5.79 (1.35) 6.53 (0.82) <0.01* 0.10
Unacceptable to use interventions without known efﬁcacy (10F) 5.42 (1.64) 6.05 (1.12) 0.04* 0.05
Unacceptable to use interventions without known cost-efﬁcacy (10G) 5.04 (1.76) 5.23 (1.57) 0.64 0.00* p-value < 0.05–two-sided.
non-intenders (1.00–3.99), and intenders (4.00–7.00)
[42,43]. In this study, a different dichotomisation yielded
comparable results on overall constructs. Multivariate
analyses of variance [MANOVA] were conducted in order
to assess whether there was an overall difference in
beliefs concerning factors (i.e., knowledge, risk perception
attitude (advantages), attitude (disadvantages), social
support and self-efﬁcacy), followed by a post-hoc analysis
for the items separately to assess differences in beliefs
between the groups. Partial 2’s were used to estimate the
effect sizes. A multiple regression analysis was conducted
to identify how well the model ﬁtted the data and to
identify the main explanatory variables of the intention to
adopt the ROI tool. A regression was used with the overall
intention scale to adopt the ROI tool as the dependent
variable. The independent variables ‘gender’, ‘stakeholder
role’, ‘country’, ‘pre-motivational factors’ (knowledge,
risk perception, and awareness), and ‘motivational fac-
tors’ (attitude, social inﬂuences, and self-efﬁcacy) were
included in the model to identify which variables were
the main explanatory variables of the intention to adopt
the ROI tool. The underlying assumptions of the regression
models were found to be satisfactory and there were no
signs of collinearity between the explanatory variables
(tolerance > 0.20 and VIF < 4.00). Despite the Likert scale
being an ordinal scale, it is argued that many studies
consistently show that parametric statistics are robust
with respect to violations of its assumptions [44].
3. Results
3.1. Sample characteristics
Of the 167 stakeholders approached in the ﬁve
countries, 93 respondents agreed to take part (56.9%
response rate). About 38% of the respondents were female.
Of the 93 respondents, 30.1% were Dutch, 17.2% Hungarian,
18.3% German, 19.4% Spanish, and 15.1% British. Respon-
dents were from different categories of stakeholders:
decision-makers (31.2%), purchasers of services/pharma
products (7.5%), professional service providers (19.4%),
evidence generators (26.9%), and advocates of health pro-
motion (15.1%). Based on their response, most stakeholders
(72.65%) could be classiﬁed as intenders (to use the ROI
tool).3.2. Differences between non-intenders and intenders in
beliefs
Intenders and non-intenders were compared in their
beliefs. The results of MANOVA (using Pillai’s trace)
revealed an overall signiﬁcant difference between non-
intenders and intenders in beliefs regarding risk percep-
tion, V = 0.24; F(7, 78) = 3.43; p = 0.00; partial 2 = 0.24,
attitude, V = 0.44; F(21, 55) = 2.08; p = 0.02; partial 2 = 0.44,
social support, V = 0.30; F(7, 67) = 4.18; p = 0.00; par-
tial 2 = 0.30, and self-efﬁcacy, V = 0.28; F(11, 69) = 2.48;
p = 0.01; partial 2 = 0.28. No overall differences were found
between non-intenders and intenders in beliefs regarding
knowledge. Separate univariate ANOVA’s further isolated
exactly where the signiﬁcant and interesting differences
were to be found.
Pre-motivational beliefs in terms of risk perception
differed between non-intenders and intenders (Table 1).
Intenders perceived the smoking epidemic as more severe
in their country, and perceived greater importance to use
smoking cessation interventions due to mortality and costs.
Motivational beliefs in terms of attitude, social
support, and self-efﬁcacy differed between intenders and
non-intenders (Table 2). Compared to non-intenders,
intenders expected more advantages of the ROI tool
in terms of its ability to provide ﬁnancial justiﬁcation,
an easy interface, up-to-date information, relevant out-
comes for the organisation, sufﬁcient scientiﬁc support
for decision-making, added value to current information,
support in choosing smoking cessation methods, integra-
tion of all relevant information, different time horizons,
assessment of cost-effectiveness of new interventions,
assessment of potential new interventions, and increased
efﬁciency in service delivery. Intenders expected fewer
signiﬁcant disadvantages of the tool (i.e., not useful, not
compatible for the organisation, and no need for daily
work) than non-intenders. Intenders also expected more
social support, i.e., from their boss, other colleagues,
organisations, reimbursement agencies, the ministry of
health, and health professionals like medical special-
ists to use the ROI tool. Moreover, intenders believed
more than non-intenders that they were able to use
the ROI tool, even when they would have to enter the
information on smoking cessation effects of programs
themselves.
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Table  2
Differences between non-intenders and intenders in beliefs: motivational factors; 1 = strongly disagree, 7 = strongly agree.
Non-intenders Intenders p-value Partial 2
Mean (SD) Mean (SD)
Attitude (advantages)
Tool having more advantages than disadvantages (13A) 5.00 (1.38) 6.33 (0.82) <0.01* 0.27
I  believe that a tool such as the Tobacco ROI tool
Provides ﬁnancial justiﬁcation (13B) 4.96 (1.69) 6.17 (0.82) <0.01* 0.19
Is  easy to use (13C) 4.87 (1.79) 5.67 (1.35) 0.04* 0.06
Provides up-to-date information (13D) 4.35 (1.43) 5.56 (1.36) <0.01* 0.14
Provides relevant outcomes (13E) 4.96 (1.58) 6.07 (1.03) <0.01* 0.15
Provides sufﬁcient scientiﬁc support (13F) 4.07 (1.66) 6.00 (1.18) <0.01* 0.17
Provides added value (13G) 5.26 (1.76) 6.28 (0.94‘) <0.01* 0.13
Helps  choosing smoking interventions (13H) 4.00 (1.98) 5.74 (1.29) <0.01* 0.22
Integrates all relevant information available (13I) 4.26 (1.98) 5.37 (1.46) <0.01* 0.09
Can  calculate outcomes over different periods (13J) 5.65 (1.61) 6.33 (0.91) 0.02* 0.07
Can  assess potential new interventions (13K) 4.35 (1.99) 5.63 (1.61) <0.01* 0.11
Helps  increase efﬁciency in service delivery (13L) 4.83 (1.78) 5.76 (1.47) 0.02* 0.07
Attitude (disadvantages)
I  believe that a tool such as the Tobacco ROI tool
Is too time consuming (13N) 3.09 (1.54) 2.70 (1.25) 0.26 0.02
Is  not useful (13O) 3.78 (2.04) 2.43 (1.59) <0.01* 0.12
Requires too much data input (13P) 3.39 (1.59) 2.87 (1.42) 0.16 0.03
Is  too complex to work with (13Q) 2.91 (1.62) 2.46 (1.24) 0.19 0.02
Is  not compatible with the way  we work (13R) 3.57 (1.93) 2.37 (1.36) <0.01* 0.11
Provides unreliable outcomes (13S) 3.26 (1.48) 2.72 (1.49) 0.15 0.03
Does  not provide insight (13T) 3.30 (1.82) 2.93 (1.71) 0.39 0.01
Results into outcomes that are too broad (13U) 2.96 (1.61) 2.76 (1.54) 0.61 0.00
Is  not needed for my  daily work (13V) 4.52 (2.00) 2.87 (1.76) <0.01* 0.15
Social support
My boss (14A) 4.14 (2.08) 6.00 (1.23) <0.01* 0.24
My  other colleagues (14B) 4.23 (2.02) 5.98 (1.15) <0.01* 0.24
My  organisation (14C) 4.05 (2.06) 5.94 (1.25) <0.01* 0.25
Reimbursement agencies (14D) 3.77 (1.82) 5.23 (1.42) <0.01* 0.16
My  ministry of health (14E) 4.36 (1.79) 5.40 (1.51) 0.01* 0.08
Health  professionals (14F) 4.27 (1.61) 5.32 (1.25) <0.01* 0.11
I  would encounter resistance (14H) 3.32 (2.01) 2.85 (2.07) 0.37 0.01
Self-efﬁcacy
Able  to use the ROI tool (14J) 5.77 (0.97) 6.31 (0.77) 0.01* 0.08
Able  to use the ROI tool when I need to enter information myself (14K) 4.95 (1.94) 5.92 (1.01) <0.01* 0.10
Able  to understand the ROI tool when the data is given in a list of ﬁgures (14L) 6.18 (0.85) 6.14 (1.07) 0.86 0.00
Able  to use the ROI tool if my  organisation does not support me  (14M) 4.18 (2.26) 4.88 (2.09) 0.19 0.02
Able  to use the ROI tool without help from others (14N) 4.86 (1.75) 5.58 (1.45) 0.07 0.04
Comparable others will be able to use the ROI tool (14O) 5.95 (0.79) 5.88 (1.05) 0.77 0.00
Able  to interpret the output (14P) 6.14 (0.83) 6.24 (0.73) 0.60 0.00
Able  to use the ROI tool with limited knowledge about health economics (14Q) 5.68 (1.25) 5.69 (1.30) 0.97 0.00
Able  to use the ROI tool without technical support (14R) 5.23 (1.45) 4.69 (1.76) 0.21 0.02
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* p-value < 0.05–two-sided.
.3. Model explaining the intention to adopt economic
ecision-support tools
A multiple linear regression analysis identiﬁed I-Change
odel constructs that signiﬁcantly explain the likelihood
f intention to use the ROI tool (see Table 3). The model
xplained a signiﬁcant proportion of the variation in inten-
ion to use, R2 = 0.69, F(15.42) = 6.11, p < 0.01. Compared
o the UK stakeholders, stakeholders from Hungary were
ore likely to have a higher intention to use the ROI tool.
vidence generators and advocates of health promotion
ere more likely to have a lower intention to use the
OI tool. Awareness of an economic tool of tobacco con-
rol was positively associated with the intention to use the
OI tool. A positive attitude of the ROI tool and the per-
eption of high social support to use the ROI tool were
lso positively associated with the intention. Self-efﬁcacy3.59 (1.76) 3.69 (1.79) 0.82 0.00
3.68 (1.64) 3.90 (1.88) 0.64 0.00
was not identiﬁed as a signiﬁcant explanatory variable for
intention.
4. Discussion
To the best of our knowledge, this is the ﬁrst study to
provide a theoretical framework to explain what makes
stakeholders – including decision-makers – to take up
economic decision-support tools in decision-making. This
study showed which relevant beliefs and theoretical con-
structs determine the intention to take up an economic
decision-support tool, like the ROI tool. These beliefs and
constructs may  also be relevant in explaining the inten-
tion to conduct the higher-order behaviour, the usage of
model-based economic evaluations in decision-making.
The ﬁnding that intenders and non-intenders differed
in their beliefs in risk perception, attitude, social support,
52 K.L. Cheung et al. / Health Poli
Table  3
Results of multiple linear regression analyses: intention predicted by
demographics, pre-motivational variables, and motivational variables.
Measure B SE B ˇ
(Constant) −5.16 1.93 –
Demographic factors
Gender 0.52 0.35 0.15
Role (ref: Decision maker)
Purchasers −0.34 0.67 −0.05
Professionals 0.03 0.53 0.01
Evidence generators −0.93* 0.45 −0.26*
Advocates −1.24* 0.58 −0.25*
Country (ref: UK)
Netherlands 0.16 0.55 0.05
Hungary 1.88* 0.84 0.31*
Spain 0.43 0.69 0.08
Germany 0.93 0.77 0.19
Pre-motivational factors
Knowledge 0.20 0.19 0.11
Risk perception 0.26 0.16 0.19
Awareness 0.76* 0.36 0.20*
Motivational factors
Attitude 0.94* 0.25 0.51*
* *Social support 0.41 0.19 0.30
Self-efﬁcacy 0.03 0.21 0.02
* p-value < 0.05–two-sided.
and self-efﬁcacy implies that those beliefs will need to
be addressed when developing and disseminating any
economic decision-support tool, like the ROI tool. Hence,
in order to stimulate dissemination of the ROI tool, the
ﬁrst step is to create awareness about the societal burden
of tobacco smoking and the risks of implementing non-
evidence based measures (e.g., that the smoking epidemic
is severe and that there is a high mortality due to the
consequences of smoking). Next, it is important to enhance
stakeholders’ attitude, of which partial 2 indicates that
44% of the between subject variance is accounted for by
attitudinal beliefs. In the communication with stakehol-
ders, it is important to stress the advantages of using an
economic decision-support tool like the ROI tool, especially
ﬁnancial justiﬁcation for decision-making, and to give clear
guidance in choosing speciﬁc smoking cessation methods.
Moreover, it is important to enhance stakeholders’ beliefs
about the social support they may  receive. In order to
increase self-efﬁcacy to use the tool and relevant skills,
(online) training outlining how to use the ROI tool is also
recommended. Furthermore, our data also shows that the
ROI tool needs to be transparent (concerning algorithms
used), reliable, user-friendly, able to yield different and
relevant outcomes over different time horizons, updated
regularly, and able to incorporate new interventions.
This study may  also add to a body of literature that con-
tributes to a better understanding of the likely facilitators
and barriers for stakeholders to use economic decision-
support tools, which may  be similar to the facilitating and
hindering factors regarding the uptake of model-based eco-
nomic evaluations in general [11,18,19]. The differences in
beliefs between intenders and non-intenders provide use-
ful insights to the mechanism by which facilitators and
barriers to take up economic evaluations interplay with
each other. Previous literature identiﬁes uncertainty in the
quality of the studies, limited applicability to the stakehol-
ders’ setting, negative attitude towards scientiﬁc evidence,cy 120 (2016) 46–54
timeliness and relevance of research, and trust in the source
of evidence as barriers for the uptake of economic evalu-
ations [11,18,19]. Interestingly, these correspond to some
of the attitudinal beliefs that we  have measured in the sur-
vey, respectively: the ROI tool “provides sufﬁcient scientiﬁc
support for decision-making”, “provides relevant outcomes
for my  organisation”, “provides added value to the informa-
tion currently used”, “can calculate the cost-effectiveness
outcomes over different periods such as 2 years, 5 years,
10 years, and lifetime”, and “integrates all relevant infor-
mation available to calculate cost-effectiveness”. Other
barriers are the lack of support for management and front-
line staff, and lack of tools and skills to interpret scientiﬁc
evidence [11], which we captured in the survey as lack of
social support by other colleagues and the perception that
they are able to use the ROI tool. Furthermore, the I-Change
Model constructs explained a large proportion of the varia-
tion in intention to use an economic decision-support tool
like the ROI tool, which is comparable with several other
studies (e.g., Godin et al. [45]). This provides us with con-
ﬁdence to suggest that facilitators and barriers indicated
in previous literature can be framed using the I-Change
model. Interesting is that self-efﬁcacy did not have a unique
contribution for understanding the intention in the model.
One explanation may  be that the ROI tool was designed
to assist stakeholders to interpret model-based economic
evidence, improving their self-efﬁcacy. Self-efﬁcacy beliefs
with regard to using the ROI tool may  be associated with
self-efﬁcacy beliefs to use model-based economic evidence
in decision making. This is reﬂected by the small effect sizes
regarding the two signiﬁcant beliefs of self-efﬁcacy.
As cross-context transferability of economic evidence is
a growing subject of investigation currently, this study pro-
vides further evidence that approaches to evidence transfer
need not concentrate solely on methods to validate an eco-
nomic model for its robustness (e.g., Welte et al. [46]); how
this model will need to be presented to stakeholders in
different countries can also play a signiﬁcant role. If trans-
ferred tools and evidence are not likely to be taken up
widely in any new context, the entire effort to transfer evi-
dence can be ineffective, regardless of the quality of the
evidence in question.
This study is not free from limitations. The ﬁndings
reﬂect cross-sectional views and intentions of stakeholders
and it is difﬁcult to know to what extent current con-
clusions would remain valid, if temporal measures were
available. A bias in the study could have emerged due to the
fact that stakeholders were told in advance a ROI tool would
eventually be developed and a prototype was shown by
means of a video. This may  have led stakeholders to change
their original position. The small sample size limited our
ability to explore the differences between intenders and
non-intenders in each country. Furthermore, as the ROI
tool was not yet available, the action phase was  not exam-
ined in this study. Yet, intentions to use do not always
predict actual use in practice. One reason may  be the lack of
freedom in decision-making at the local level. Additionally,
translating intentions successfully also requires making
very speciﬁc action plans, also referred to as implementa-
tion intentions [39]. Forming an implementation intention
(plans that specify when, where, and how one will perform
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he behaviour; if x, then behaviour y) has shown to
mprove rates of behavioural enactment, by delegating
ontrol of behaviour to speciﬁed situational cues [39,47]. It
s therefore relevant for future studies to explore methods
o enhance translations of plans into actual behaviour.
Lastly, one assumption of our approach is that decision-
aking concerning the adoption of ROI tools will occur
ased on sound rational decision-making, whereas this
ay  not always be the case and may  also be based on other
actors, such as system rigidities, value conﬂict and com-
eting objectives. Hence, it is important to also consider
he wider array of contexts inﬂuencing this process [23].
. Conclusions
This is the ﬁrst study to propose a theoretical framework
o explain what makes stakeholders including decision-
akers to use economic decision-support tools on tobacco
ontrol. The empirical results based on the I-Change model
ndicate that pre-motivational and motivational factors
i.e., awareness, attitude, and social support) explain a
igniﬁcant proportion of variation in stakeholders’ inten-
ion to take up an economic decision-support tool. Future
ommunication strategies to promote the use of economic
ecision-support tools among stakeholders should there-
ore focus on those factors, for example, by highlighting the
dvantages of such tools for decision-making.
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